| Application no. and date | 03755724.6 (espacenet) (Federated) (European Patent Register), 20030711 | | Patent/reg. no. and date | DK/EP 1585966, 20111130 | | Publication date | 20051019 | | Priority no. and date | US 396290 P, 20020715, US 480043 P, 20030620 | | EP pub. no. and date |
EP 1585966 20051019 | | Effective date | | | Applicant/owner | F. Hoffmann-La Roche AG, Grenzacherstrasse 124
4070 Base, CH | | Applicant ref. no. | 156282 | | Inventor | KOLL, Hans, Blütenanger 45
85247 Oberroth, DE,
MÜLLER, Hans-Joachim, Ruhe am Bach 5 b
82377 Penzberg, DE,
KELSEY, Stephen, Michael, 360 14th Street
Montara, CA 94037, US,
SLIWKOWSKI, Mark, X., 42 Oak Creek Lane
San Carlos, CA 94070, US,
BOSSENMAIER, Birgit, Horst-Wolfram-Geissler-Weg 10
82229 Seefeld, DE | | Representative | AWA Denmark A/S, Strandgade 56, 1401 København K, DK | | Opponent | | | IPC Class | A61K 39/395 (2006.01) | | Title | Behandling af cancer med anti-ErbB2-antistoffet rhuMab 2C4 | | Int. application no. | US2003021590 | | Int. publication no. | WO2004008099 | | Related patent (certificate) | | | Status | Udløbet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
